EPO and myeloproliferative disorder: In this study, we demonstrate for the first time across multiple animal models that FHF significantly alleviates MPN progression, including EPO-induced polycythemia vera (PV)-like, JAK2<sup>V617F</sup>-driven PV, and MPL<sup>W515L</sup>-driven essential thrombocythemia (ET) models.